Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

In-vivo activated T-cell depletion to prevent GVHD.

Trial Profile

In-vivo activated T-cell depletion to prevent GVHD.

Phase of Trial: Phase II/III

Latest Information Update: 19 Mar 2012

At a glance

  • Drugs Basiliximab (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine; Mycophenolate mofetil
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Mar 2012 Actual patient number changed from 11 to 10 as reported by ClinicalTrials.gov.
    • 06 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top